Wall Street Analysts Think Sensus Healthcare (SRTS) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Sensus Healthcare: Recurring Revenue Initiatives Are Exciting
Sensus Healthcare offers equipment for skin problems, with strong demand but vulnerable to economic instability. The company is recovering in 2024, with initiatives for recurring revenue to improve income stability through software and maintenance services. It has begun its expansion to Asia, which in the future could mitigate the risk of customer concentration.
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
Here is how Sensus Healthcare, Inc. (SRTS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Sensus Healthcare, Inc. (SRTS) Recently Broke Out Above the 20-Day Moving Average
From a technical perspective, Sensus Healthcare, Inc. (SRTS) is looking like an interesting pick, as it just reached a key level of support. SRTS recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Sensus Healthcare (SRTS) is on the Move, Here's Why the Trend Could be Sustainable
Sensus Healthcare (SRTS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 64.74%: Here's is How to Trade
The consensus price target hints at a 64.7% upside potential for Sensus Healthcare (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sensus Healthcare, Inc. (SRTS) Q2 2024 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA, IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Jason Wittes - ROTH Anthony Vendetti - Maxim Group Eduardo Martinez-Montes - H.C. Wainwright & Co. Operator Good day and welcome to the Sensus Healthcare Second Quarter 2024 Financial Results Conference Call.
Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Beat Estimates
Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.02 per share a year ago.
Buying Great Under-the-Radar Stocks During the August Market Pullback
Investors who want to buy stocks in August might consider searching for stocks gaining more attention from Wall Street. Today we dive into Sensus Healthcare (SRTS) stock and more.
Sensus Healthcare, Inc. (SRTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.25, representing a -1.88% change from its previous close.
Sensus Healthcare, Inc. (SRTS) Earnings Expected to Grow: Should You Buy?
Sensus Healthcare (SRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent Price Trend in Sensus Healthcare (SRTS) is Your Friend, Here's Why
Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
